ELF

Analyst Note: e.l.f. Beauty, Inc. (ELF)

Date: 2026-06-13 Current Price: $64.20

1. Structural Readiness

• State: Context-only.
• Conservative Entry: Not yet actionable (requires confirmed breakout).
• Aggressive/Pre-Breakout Entry: Not defined in the provided parameters.
• Breakout Level: Not yet fired.
• Current Price: $64.20.
• Extension: Not defined.
• ATR Context: Current ATR is 6.0% (High). This indicates elevated volatility, which is a key input for position sizing but does not alter the structural validity of the forming coil.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Macro Thesis: There is no named secular thesis attached to this name as of 2026-06-13.
• Judgment Framework: The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals (growth, margin expansion, and integration success). No external macro narratives should be invented to support the position.

3. Business Overview

e.l.f. Beauty, Inc. operates as a multi-brand beauty company offering inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skincare products. The company's business model relies on a "value proposition" combined with "powerhouse innovation and disruptive marketing" to drive market share gains in a concentrated industry.

• Brand Portfolio: As of the latest filings (2026-02-05 and 2026-05-21), the family includes e.l.f. Cosmetics, e.l.f. SKIN, Naturium, Well People, Keys Soulcare, and rhode.
• Financial Performance (Fiscal '26):
• Growth: In fiscal '26, the company grew net sales by 25% and adjusted EBITDA by 13% (Source: E1).
• Rhode Integration: The acquisition of HRBeauty LLC ("rhode"), consummated on August 5, 2025, for $897.5 million, is a primary growth driver. Rhode contributed approximately $140 million in net sales in the first four months of the fiscal year and delivered over $500 million in global retail sales, growing net sales over 80% year-over-year (Source: E3, E5).
• Total Scale: The company delivered approximately $1.8 billion in global retail sales for the year (Source: E4).
• Market Share: e.l.f. Cosmetics increased its U.S. market share by 115 basis points in fiscal '26, the largest gain among nearly 1,000 tracked brands (Source: E7).
• Distribution: The company maintains strong relationships with major retailers including Target (18% of net sales), Walmart (13%), Amazon (11%), and Sephora (10%) (Source: E17). National and international retailers comprised 76% of net sales, with e-commerce at 24% (Source: E19).
• Geography: The United States accounted for 79% of net sales, with international markets at 21% (Source: E20).
• Marketing Efficiency: Marketing and digital expenses totaled $399.8 million, representing approximately 24% of net sales (Source: E21).
• Pricing Strategy: To mitigate tariff risks, the company raised prices globally for all products as of August 1, 2025 (Source: E14).
• Future Guidance (Management Expectations):
• For the full year, management expects net sales growth of 12% to 14%.
• Adjusted EBITDA is expected between $379 million to $385 million.
• Adjusted Net Income is expected between $198 million to $201 million.
• Adjusted EPS is expected between $3.27 to $3.32 (Source: E2).
• Management anticipates the annualization of the Rhode acquisition to contribute approximately 9 percentage points to full-year net sales growth (Source: E3).
• Expansion plans include launching Rhode in Sephora across 19 European countries in September 2026 (Source: E8).

4. Archetype and Conviction

• Archetype: Quality Compounder.
• *Rationale:* The company demonstrates consistent double-digit sales growth, successful M&A integration (Rhode), and significant market share gains in a competitive landscape. The ability to scale multiple brands (e.l.f., Rhode, Naturium) while maintaining a value price point ($7 average vs. $10 mass/$30 prestige) supports a compounder profile.
• Valuation Context:
• Forward consensus EPS for FY1 is $3.10 and FY2 is $3.30 (Source: E28).
• Management guidance for FY26 adjusted EPS is $3.27–$3.32, which aligns closely with the FY2 consensus, suggesting the market is pricing in the guidance.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm growth, integration success, and clear guidance.
• Rerating Potential: Dependent on the successful execution of the Rhode integration and the expansion into Europe.

5. Invalidations, Strengths, and Gaps

• Invalidation Triggers:
• Failure to meet the full-year guidance of 12-14% net sales growth or $379M+ EBITDA.
• Significant degradation in Rhode's growth trajectory (currently >80% YoY).
• Strengthening Factors:
• A confirmed breakout above the current consolidation range.
• Successful launch of Rhode in 19 European Sephora locations (Source: E8).
• Continued market share gains (currently +115 bps).
• Evidence Gaps:
• No named secular thesis: The analysis relies entirely on company-specific execution rather than a broader market tailwind.
• Tariff Impact: While price hikes were implemented (Source: E14), the long-term elasticity impact on volume is not explicitly quantified in the provided evidence.
• International Mix: International sales remain a small portion (21%) of the total; the success of the European expansion is a key unknown variable.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Fiscal '26 net sales grew 25% with 115 bps market share gain; Rhode acquisition contributed $140M in first 4 months and is projected to add 9 percentage points to full-year growth; Management guidance for FY26 EPS ($3.27-$3.32) aligns with forward consensus. Key risks: Technical setup is forming but not yet confirmed (breakout not fired); International expansion success is unproven; Tariff mitigation via price hikes may impact volume elasticity. Sizing hint: Position size should reflect the "forming" status and high ATR (6.0%), treating this as a partial conviction play pending breakout confirmation. Expected path: Management expects 12-14% sales growth and 9 percentage points from Rhode annualization; European launch in September 2026 is a key catalyst for international revenue. Expected horizon: 3 to 6 months to observe breakout confirmation and European launch execution.